Cargando…

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

OBJECTIVE: Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body weight in obese subjects through increased energy expenditure and decreased energy intake. The metabolic effects of OXM have been attributed primarily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pocai, Alessandro, Carrington, Paul E., Adams, Jennifer R., Wright, Michael, Eiermann, George, Zhu, Lan, Du, Xiaobing, Petrov, Aleksandr, Lassman, Michael E., Jiang, Guoqiang, Liu, Franklin, Miller, Corey, Tota, Laurie M., Zhou, Gaochao, Zhang, Xiaoping, Sountis, Michael M., Santoprete, Alessia, Capito', Elena, Chicchi, Gary G., Thornberry, Nancy, Bianchi, Elisabetta, Pessi, Antonello, Marsh, Donald J., SinhaRoy, Ranabir
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750209/ https://www.ncbi.nlm.nih.gov/pubmed/19602537 http://dx.doi.org/10.2337/db09-0278

Ejemplares similares

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
por: Kosinski, Jennifer R., et al.
Publicado: (2012)

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
por: Galsgaard, Katrine D., et al.
Publicado: (2022)

Glucagon signaling in the heart: Activation or inhibition?()
por: Pocai, Alessandro
Publicado: (2014)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?
por: Pocai, Alessandro
Publicado: (2019)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice
por: More, Vijay R., et al.
Publicado: (2017)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells
por: Elmelund, Emilie, et al.
Publicado: (2022)

Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library
por: Demartis, Anna, et al.
Publicado: (2018)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon : its role in physiology and clinical medicine
Publicado: (1977)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016)

Beginning of a new era in glucagon research: Breakthrough by the new glucagon assay
por: Kawamori, Dan
Publicado: (2020)

Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”
por: Müller, Timo D., et al.
Publicado: (2020)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels
por: Åm, Marte Kierulf, et al.
Publicado: (2020)

Disruption of the glucagon receptor increases glucagon expression beyond α-cell hyperplasia in zebrafish
por: Kang, Qi, et al.
Publicado: (2022)

Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart
por: Aranda-Domene, Ramón, et al.
Publicado: (2023)

Copeptin under glucagon stimulation
por: Lewandowski, Krzysztof C., et al.
Publicado: (2015)

Insulin and Glucagon: Partners for Life
por: Holst, Jens Juul, et al.
Publicado: (2017)

Glucagon contributes to liver zonation
por: Cheng, Xiping, et al.
Publicado: (2018)

Metabolic effects of glucagon in humans
por: Adeva-Andany, María M., et al.
Publicado: (2018)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucagon Regulation of Energy Expenditure
por: Kleinert, Maximilian, et al.
Publicado: (2019)

Increased biogenesis of glucagon-containing secretory granules and glucagon secretion in BIG3-knockout mice
por: Li, Hongyu, et al.
Publicado: (2015)

Misrouting of glucagon and stathmin-2 towards lysosomal system of α-cells in glucagon hypersecretion of diabetes
por: Asadi, Farzad, et al.
Publicado: (2021)

Single-molecule analysis reveals that a glucagon-bound extracellular domain of the glucagon receptor is dynamic
por: Liu, Ting, et al.
Publicado: (2023)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Glucagon-producing cells are increased in Mas-deficient mice
por: Felix Braga, Janaína, et al.
Publicado: (2016)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome
por: Hao, Yongna, et al.
Publicado: (2022)

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
por: Yang, Jianxin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5ivvk9khq4hs8huendmp21912u